WWW goes WWWW: Searching is now sorted! The Web 2.0 for real

Transinsight, provider of knowledge-based software solutions, has released a new online version of the well-known life-science search engine www.GoPubMed.org. This, the first semantic search engine, reduces search time by up to 90%. By sorting search results it enables scientists to answer biomedical questions in completely new way.

The latest version of the search machine sorts all relevant documents to the top level categories What, Who, Where and When. This way, for the first time in search history, it is possible to design searches on both content and metadata in a seamlessly integrated way. Dr. Michael R. Alvers, CEO of Transinsight, points out that the opportunity for a user to rank the search results according to personal needs is revolutionary. "We don't rank, the user does!" says Alvers. "With our semantic technology we put the user at the centre of the search. Ranking algorithms like Google's PageRank are not relevant for us anymore since with our search technology the user is in the driver's seat. Also the folksonomy feature to curate matches is new and makes the Web 2.0 now and here!" continues Alvers enthusiastic.

Classical search engines are successful in helping users find information based on keywords. But they are not successful in answering complex questions. Knowledge searches are needed to answer the complex questions which are so predominant in the life sciences. Knowledge, however, is hardly ever used in traditional search engines. The new version of the search engine GoPubMed is based on two knowledge networks containing more than 120,000 terms: Gene Ontology (GO) and the Medical subject headings (MeSH). This allows biologists and medical doctors to find the needle in the haystack in both the bio-molecular and the medical domains.

"In GoPubMed the search is sorted; sorting documents into highly organised networks such as GO and MeSH facilitates the finding of relevant documents and the answering of questions with significant ease!" says Michael Schroeder, Professor for Bioinformatics at TU Dresden and CSO and Co‑Founder of Transinsight. "The use of GoPubMed can result in time savings of up to 90%. Consider the search for Aspirin, for example. With other search engines one gets more than 40,000 results for this term; by using GoPubMed's subtle mechanism for refining searches these 40,000 can be reduced to the 9 relevant to, say, coronary thrombosis. Finding these 9 articles with traditional technology takes several hours and the searcher has to have enormous knowledge in the field of coronary thrombosis. With GoPubMed even untrained students find these relevant articles within 3 seconds."

This enormous potential has been experienced not only in academia but also by big enterprises like Unilever, Elsevier, Statoil and Shell. The time these companies save with Transinsight's technology can now be used to act, instead of performing tedious searches.

"It is quite impressive to see the progress in GoPubMed. The possibility to seamlessly search PubMed, the web, the local desktop and corporate intranets on base of a knowledge-base makes the Web 2.0 reality for biologists and medical doctors" says David Ruslan, provider of www.WorldPharmaNews.com.

About Transinsight
Founded in 2005, Transinsight is focused on software solutions for the life sciences providing products for knowledge-based technologies. The flagship product, www.GoPubMed.org, a well established biomedical search engine, is the first knowledge-based search engine for the Life Sciences on the Internet. Transinsight is headquartered in one of the leading German biotech incubators, the BioInnovationCenter Dresden BIOZ, where science and business work under one roof. Transinsight works in close collaboration with the Technical University Dresden.

Most Popular Now

Swissmedic begins rolling review of Moderna's mRNA…

Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Moderna's COVID-19 vaccine candidate meets its pri…

Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for...

Pfizer and BioNTech conclude Phase 3 study of COV…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based...

Pfizer and BioNTech to submit Emergency Use Author…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced they will submit a request today to the U.S. Food and Drug Administration (FDA) for Emergency Use Authori...

Phase 2 trial of Oxford COVID-19 vaccine in health…

The UK's vaccine against SARS-CoV-2 shows similar safety and immunogenicity results in healthy older adults (aged 56 years and over) to those seen in adults aged 18-55 ye...

Lilly's neutralizing antibody bamlanivimab (LY-CoV…

The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for Eli Lilly and Company's (NYSE: LLY) investigational neutralizing antibody bamlan...

Chinese vaccine candidate based on inactivated SAR…

Results from an early-phase randomised clinical trial of a Chinese vaccine candidate based on the inactivated whole SARS-CoV-2 virus (CoronaVac) are published in The Lanc...

Medicago and GSK announce start of Phase 2/3 clini…

Medicago, a biopharmaceutical company headquartered in Quebec City, and GSK have announced the start of Phase 2/3 clinical trials of its plant-derived vaccine candidate f...

European Commission approves contract with BioNTec…

Today, the European Commission approved a fourth contract with pharmaceutical companies BioNTech and Pfizer, which provides for the initial purchase of 200 million doses ...

Pre-existing coronavirus antibodies could help pro…

Researchers at the Francis Crick Institute and University College London have found that some antibodies, created by the immune system during infection with common cold c...

Fluvoxamine may prevent serious illness in COVID-1…

In a preliminary study of COVID-19 patients with mild-to-moderate disease who were attempting to recover in their homes, researchers at Washington University School of Me...

The Sputnik V COVID-19 vaccine efficacy amounted t…

The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Rus...